What the evidence says. Early or small human trials; promising but not yet conclusive.
What is Akkermansia muciniphila?
Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)) is a probiotic strain used for improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo). NutriDex grades the human evidence as Preliminary. Akkermansia muciniphila in its PASTEURIZED form is a next-generation postbiotic whose best human evidence is for cardiometabolic risk in overweight/obese insulin-resistant adults. A 2019 randomized double-blind proof-of-concept trial (Depommier, Nature Medicine, 32 completers) found pasteurized cells, but not live cells, significantly improved insulin sensitivity (+28.6%, P=0.002), lowered insulinemia and total cholesterol versus placebo. A larger 2026 RCT (n=90) showed pasteurized A. muciniphila MucT reduced post-diet weight regain (1.2 vs 3.2 kg, P=0.012). Evidence remains preliminary: trials are small/few, paradoxically the heat-killed (postbiotic) form outperforms live cells, and outcomes were exploratory rather than confirmatory.
Purported Benefits
✓Improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo)
✓Reduces fasting insulinemia and plasma total cholesterol
✓Lowers post-diet body-weight regain and supports weight-loss maintenance
✓Reinforces the intestinal mucus layer and gut-barrier integrity (mechanistic, via Amuc_1100/TLR2 signaling)
✓Reduces markers of metabolic endotoxemia and low-grade inflammation
✓Favorably shifts cardiometabolic risk markers (modest reductions in fat mass, body weight)
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
~10^10 cells/day (10 billion) of pasteurized A. muciniphila, oral, taken daily; EFSA novel-food authorization permits up to 3.4 x 10^10 cells/day. Trial regimens ran 3-6 months; effects on insulin sensitivity emerged by ~12 weeks.
Active Compounds
Pasteurized A. muciniphila MucT (type strain ATCC BAA-835)Live A. muciniphila (proof-of-concept comparator; less effective than pasteurized)Amuc_1100 outer-membrane protein (heat-stable active component)Branded: The Akkermansia Company / Pendulum AkkermansiaOther characterized strains: YGMCC2645, Timepie001 (preclinical)
Safety & Cautions
⚠
Well tolerated in trials over 3-6 months with no treatment-related serious adverse events; mild GI symptoms only. EFSA (2021) authorized pasteurized A. muciniphila as a novel food up to 3.4x10^10 cells/day for adults; it is a non-toxigenic, avirulent commensal. Caution as a general principle for next-generation probiotics: avoid in critically ill, severely immunocompromised, or those with central venous catheters/compromised gut barrier until more safety data exist. Pasteurized (non-viable) form mitigates any theoretical live-organism translocation risk. Not studied in pregnancy or children. Educational only — always check with your doctor or pharmacist before combining Akkermansia muciniphila with any medicine.
Akkermansia muciniphila is most often taken for Improves insulin sensitivity in overweight/obese insulin-resistant adults (pasteurized form, +28.6% vs placebo), Reduces fasting insulinemia and plasma total cholesterol, Lowers post-diet body-weight regain and supports weight-loss maintenance, Reinforces the intestinal mucus layer and gut-barrier integrity (mechanistic, via Amuc_1100/TLR2 signaling). The mucin-degrading "next-generation" postbiotic for metabolic health
Does Akkermansia muciniphila work — what does the evidence say?
Preliminary evidence. Early or small human trials; promising but not yet conclusive. Akkermansia muciniphila in its PASTEURIZED form is a next-generation postbiotic whose best human evidence is for cardiometabolic risk in overweight/obese insulin-resistant adults. A 2019 randomized double-blind proof-of-concept trial (Depommier, Nature Medicine, 32 completers) found pasteurized cells, but not live cells, significantly improved insulin sensitivity (+28.6%, P=0.002), lowered insulinemia and total cholesterol versus placebo. A larger 2026 RCT (n=90) showed pasteurized A. muciniphila MucT reduced post-diet weight regain (1.2 vs 3.2 kg, P=0.012). Evidence remains preliminary: trials are small/few, paradoxically the heat-killed (postbiotic) form outperforms live cells, and outcomes were exploratory rather than confirmatory.
What is the typical dose of Akkermansia muciniphila?
~10^10 cells/day (10 billion) of pasteurized A. muciniphila, oral, taken daily; EFSA novel-food authorization permits up to 3.4 x 10^10 cells/day. Trial regimens ran 3-6 months; effects on insulin sensitivity emerged by ~12 weeks.
Is Akkermansia muciniphila safe? Any cautions or side effects?
Well tolerated in trials over 3-6 months with no treatment-related serious adverse events; mild GI symptoms only. EFSA (2021) authorized pasteurized A. muciniphila as a novel food up to 3.4x10^10 cells/day for adults; it is a non-toxigenic, avirulent commensal. Caution as a general principle for next-generation probiotics: avoid in critically ill, severely immunocompromised, or those with central venous catheters/compromised gut barrier until more safety data exist. Pasteurized (non-viable) form mitigates any theoretical live-organism translocation risk. Not studied in pregnancy or children.
How many studies support Akkermansia muciniphila?
NutriDex cites 8 sources for Akkermansia muciniphila, graded "Preliminary".
Cite this page
APA
Peh, D. (2026). Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/akkermansia
BibTeX
@misc{nutridex_akkermansia,
author = {Peh, Daryl},
title = {Akkermansia muciniphila (Akkermansia muciniphila (pasteurized)): Benefits, Dosage, Side Effects \& Evidence},
year = {2026},
howpublished = {NutriDex --- The Supplement Research Compendium},
url = {https://nutridex.info/s/akkermansia},
note = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}
For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.